Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.
CollPlant Biotechnologies Ltd (NASDAQ: CLGN) is a regenerative and aesthetic medicine company whose news flow centers on its recombinant human collagen (rhCollagen) platform, 3D bioprinting activities and medical aesthetics programs. The company regularly issues updates on its rhCollagen-based BioInk products for 3D bioprinting of tissues and organs, tissue repair solutions and aesthetics-focused product candidates.
Investors following CLGN news can expect coverage of financial results reported via quarterly updates, including revenue trends from business collaborators, BioInk sales and tendon repair and wound healing products. CollPlant also reports on clinical and non-clinical milestones for its photocurable dermal and soft tissue filler program, regenerative breast implant development and its collaboration with AbbVie and Allergan on dermal and soft tissue fillers.
Another key news theme is scientific and research collaborations. CollPlant highlights studies such as the Technion – Israel Institute of Technology comparison of its Collink.3D bioink with Matrigel, and Mayo Clinic’s work on a fully humanized 3D bioprinted skin model using plant-derived rhCollagen. These items illustrate how the company’s materials are used in tissue engineering, disease modeling and non-animal alternatives for preclinical research.
Corporate and commercial updates are also frequent, including announcements about expansion of Vergenix STR tendon-repair product distribution in Europe, establishment of a North American logistics center for rhCollagen and BioInk distribution, and participation in industry conferences and investor events. For readers tracking developments in rhCollagen-based biomaterials, 3D bioprinting and aesthetic medicine, the CLGN news page provides an ongoing stream of company-generated information and regulatory disclosures.
CollPlant Biotechnologies (Nasdaq: CLGN) said it will report full-year 2025 financial results on Thursday, March 26, 2026, before the opening of U.S. financial markets. The announcement sets a date for earnings disclosure and signals when investors can expect results and related company materials.
CollPlant (Nasdaq: CLGN) announced the Korean Patent Office allowed a patent for its photocurable dermal filler covering a polymerizable rhCollagen solution for in situ light-activated tissue augmentation.
The allowance extends protection through 2039, follows a recent Japanese grant, and adds to granted patents in the US, Europe, China, Brazil, Australia, and Israel. According to the company, the global injectable soft-tissue filler market exceeds $6 billion. CollPlant noted a 2021 development and global commercialization agreement with Allergan (AbbVie).
CollPlant (NASDAQ: CLGN) launched BioFlex, a ready-to-print rhCollagen kit for DLP 3D bioprinting, aimed at drug discovery, engineered tissues and organ fabrication.
BioFlex bundles Collink.3D 50 biodegradable polymer with proprietary photoactive agents and formulation guidelines to enable tunable, high-resolution, reproducible bioinks and faster development.
CollPlant (NASDAQ: CLGN) announced Feb 17, 2026 strategic positioning of a photocurable rhCollagen dermal filler to address facial volume loss linked to rapid weight loss, including patients on GLP-1 therapies. The platform is preclinical and aims to restore structure, integrate with tissue, and potentially improve skin quality over time.
The company is evaluating clinical and commercial pathways to address a growing aesthetic need driven by expanding GLP-1 use.
CollPlant (NASDAQ: CLGN) entered a definitive agreement for a registered direct offering of 1,600,000 ordinary shares at $1.25 per share for gross proceeds of approximately $2.0 million. Concurrently, unregistered Series A and B warrants to purchase up to 1,600,000 shares each will be issued.
The Series A warrants have a $1.25 exercise price and expire five years after the effective registration date; Series B warrants have a $1.25 exercise price and expire 18 months after that date. The offering is expected to close on or about February 6, 2026, with H.C. Wainwright as placement agent.
CollPlant Biotechnologies (Nasdaq: CLGN) reported third-quarter 2025 results and a corporate update on Nov 26, 2025. Key commercial moves include a new U.S. logistics center becoming operational this quarter and appointment of a North America commercial head to expand rhCollagen and BioInk distribution.
Financial highlights: Q3 GAAP revenue $77k (vs $4k year-ago); 9M revenue $2.3M driven by a $2.0M AbbVie milestone; cash $8.5M as of Sept 30, 2025; GAAP 9M net loss narrowed to $8.3M from $12.7M. Company initiated a ~25% workforce reduction and cost-prioritization to extend runway.
CollPlant Biotechnologies (Nasdaq: CLGN) announced it will report third quarter 2025 financial results on Wednesday, November 26, 2025, before the U.S. market open. The company develops non-animal-derived rhCollagen products for tissue regeneration and medical aesthetics. Investors can expect the company to release results and any accompanying commentary or materials on that date.
CollPlant (Nasdaq: CLGN) announced an expansion of its North American distribution through a new U.S.-based logistics center, scheduled to become operational this quarter (announcement dated Oct 27, 2025).
The hub will provide full cGMP-compliant storage and distribution, serve as a clinical supply depot, and support rhCollagen and BioInk product lines in the U.S. and Canada. Facility features include cGMP-controlled environments, cloud-based temperature monitoring, advanced emergency backup, AI-powered security, and remote inventory management.
Management said local inventory and improved logistics are expected to increase efficiency, reduce shipping time, and strengthen support for customers and clinical partners in North America.
CollPlant (Nasdaq: CLGN) announced that a head-to-head study by Technion's Levenberg Lab found its rhCollagen-based bioink Collink.3D™ outperformed Matrigel® on key lab metrics. Collink.3D™ reportedly showed enhanced mechanical strength, elasticity, and stability, supporting organized and long-lasting tissue formation in a reproducible, animal-free format.
The release highlights potential application in tissue engineering, regenerative medicine, and drug discovery and notes the global basement membrane matrix market was ~$96M in 2024, projected to reach $201M by 2031 (CAGR 11.2%).
CollPlant (NASDAQ: CLGN) said Mayo Clinic researchers developed a first‑in‑kind fully humanized 3D bioprinted human skin model using CollPlant's plant‑derived recombinant human collagen (rhCollagen) bioink, announced Oct. 16, 2025.
The model combines rhCollagen bioinks with human fibroblasts, melanocytes and keratinocytes and is integrated into a skin‑on‑a‑chip system to evaluate topical and transdermal drug delivery as a non‑animal preclinical platform. Claimed advantages include high‑throughput production, personalized human skin models at scale, reduced animal testing, and potential use in cosmetic and pharmaceutical testing, disease modeling, drug development and regenerative medicine.